SELLAS Life Sciences Group, Inc. (SLS) vs GeneDx Holdings Corp. (WGS)

A side-by-side comparison of SELLAS Life Sciences Group, Inc. and GeneDx Holdings Corp. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.

Compare

Total return — SLS vs WGS

growth of $100 · dividends reinvested · last 6y
SLS +365.2% (+29.2%/yr)WGS -76.4% (-21.4%/yr)SLS compounded faster over this window
Log scale — wide-divergence pair
01101001kStart $100202120222023202420252026$465$24
SLS WGS

SLS vs WGS: by the numbers

  • •WGS is the larger company ($2.13B vs $2.13B market cap).
  • •Both run net losses; SLS's is the smaller (0.00% vs -23.40% net margin).

Metrics side by side

Valuation

MetricSLSWGS
P/S ratioN/A4.70
P/B ratio15.448.74

Profitability

MetricSLSWGS
Gross margin0.00%68.20%
Operating margin0.00%-2.76%
Net margin0.00%-23.40%
ROE-23.58%-43.55%
ROIC-25.45%-14.69%

Growth (annualized)

MetricSLSWGS
Revenue CAGR (5Y)N/A16.28%
Total return CAGR (5Y)6.20%-19.67%

Frequently asked

How have SLS and WGS total returns compared?
Over the past 5 years, SLS delivered 6.20% and WGS delivered -19.67% annualized total return. Past performance doesn't predict future results.

Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.